Evelo Biosciences, Inc. (EVLO) Financials

EVLO Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2023 20.6 million 47.3 million
June 30, 2023 20.8 million 66.9 million
March 31, 2023 42.0 million 69.4 million
Dec. 31, 2022 64.4 million 69.4 million

EVLO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -10.5 million 2.5 million
June 30, 2023 -19.8 million 2.4 million
March 31, 2023 -20.3 million 2.9 million
Dec. 31, 2022 -23.4 million 3.4 million

EVLO Net Income

No data available :(

EVLO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 17.3 million - -
June 30, 2023 7.6 million 3.9 million 2.7 million
March 31, 2023 27.5 million - 6.9 million
Dec. 31, 2022 47.9 million 43.6 million 7.5 million

EVLO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 17.4 million
June 30, 2023 5.6 million
March 31, 2023 5.5 million
Dec. 31, 2022 5.5 million

EVLO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 47000 6.5 million 3.9 million -
June 30, 2023 - 13.0 million 4.9 million -
March 31, 2023 12000 17.9 million 7.0 million -
Dec. 31, 2022 228000 16.1 million 5.0 million -

EVLO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 - 793000
June 30, 2023 - 1.6 million
March 31, 2023 - -
Dec. 31, 2022 - -

EVLO

Price: $0

52 week price:
0.00
0.00

Earnings Per Share: -19.55 USD

P/E Ratio: -1.81

Exchange: OEM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 71715

Market Capitalization: 1898

Links: